Department of Medicine
-
May 23, 2023
Treating kidney injury before it happens
Pretreatment of an animal model with a novel compound called PHAD reduced kidney injury, suggesting it may be a good candidate for preventing kidney injury in surgical patients. -
May 18, 2023
New view of mutations informs disease risk, treatment response
A transcontinental research effort led by scientists from Vanderbilt University Medical Center and the University of Michigan has upended some long-standing assumptions about mutations — how often they occur, what causes them and what they do. -
May 11, 2023
Bauml, Wright land eStar Physician Builder Awards
Vanderbilt radiologist and clinical informatics fellow Julie Bauml, MD, and internal medicine specialist Aileen Wright, MD, have received 2023 Physician Builder Awards. -
May 11, 2023
Lovly elected to American Association for Cancer Research board
Christine Lovly, MD, PhD, has been elected to the American Association for Cancer Research board of directors. -
May 11, 2023
Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments
The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer. -
May 9, 2023
Neural networks probe proteins
A machine learning method based on neural networks outperformed a mutational scanning model at identifying disease-causing mutations in an Alzheimer’s disease protein, suggesting the method could be useful for facilitating therapeutic design. -
May 8, 2023
Diabetes drugs associated with fewer adverse cardiac events in older veterans: study
Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.